Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 147 | 8,757 | 45% |
| 2020 | 122 | 7,594 | 51% |
| 2021 | 140 | 8,641 | 55% |
| 2022 | 143 | 8,947 | 59% |
| 2023 | 142 | 7,904 | 63% |
| 2024 | 128 | 7,269 | 66% |
| 2025 from claims | – | 7,718 7,083–8,165 | 67% |
| 2026 forecast | – | 7,891 6,943–9,106 | 67% |
| 2027 forecast | – | 7,985 6,826–9,515 | 68% |
| 2028 forecast | – | 8,075 6,738–9,888 | 69% |
| 2029 forecast | – | 8,162 6,666–10,235 | 70% |
| 2030 forecast | – | 8,244 6,605–10,565 | 70% |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 23% of the cases CMS names in Michigan; 72 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 25% hospital outpatient, 15% surgery center, 60% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 165 | 12,036+1%/yr | +1%/yr | 8.4 | 66% | 13,800 in 2030+2.3%/yr |
| Ohio | 179 | 10,830−5.3%/yr | −5.3%/yr | 9.3 | 43% | 11,600 in 2030+1.2%/yr |
| Indiana | 117 | 6,614−1.7%/yr | −1.7%/yr | 9.0 | 71% | 8,050 in 2030+3.3%/yr |
| Missouri | 93 | 6,170+1.6%/yr | +1.6%/yr | 9.5 | 28% | 8,640 in 2030+5.8%/yr |
| Wisconsin | 107 | 5,630−0.5%/yr | −0.5%/yr | 9.5 | 45% | 6,580 in 2030+2.6%/yr |
| Minnesota | 88 | 4,824+0.9%/yr | +0.9%/yr | 10.1 | 73% | 6,880 in 2030+6.1%/yr |
| Kansas | 57 | 3,413+4%/yr | +4%/yr | 8.2 | 46% | 4,450 in 2030+4.5%/yr |
| Nebraska | 37 | 2,646+7.2%/yr | +7.2%/yr | 9.8 | 71% | 4,000 in 2030+7.1%/yr |
| Iowa | 36 | 2,386+2.2%/yr | +2.2%/yr | 5.2 | 62% | 2,800 in 2030+2.7%/yr |
| South Dakota | 16 | 1,153−1.6%/yr | −1.6%/yr | 8.6 | 12% | 1,270 in 2030+1.6%/yr |
| North Dakota | 12 | 670−3.9%/yr | −3.9%/yr | 6.5 | 37% | 740 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 9 | 674−6.2%/yr | −6.2%/yr | 0.70.6× | 49% | 680 in 20300%/yr |
| Spinal cord & DRG stimulation | 13 | 535−8.6%/yr | −8.6%/yr | 0.60.8× | 51% | 480 in 2030−1.9%/yr |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Illinois
Nalu Medical leads with 60% of company spending on these surgeons in 2025, +23 pts on 2024.
In 2025, 6 companies reported engagement with Michigan’s surgeons worth $137K in consulting, speaking, meals and travel tied to these products, about $1,069 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.